Navigation Links
Sanofi-aventis Delivers 2008 Results Above Guidance
Date:2/11/2009

2009 guidance

  • In 2009, sanofi-aventis expects growth in adjusted EPS excluding selected items(1) of at least 7% at constant exchange rates, barring major adverse events such as the launch of a generic of Lovenox(R) in the United States

* Unless otherwise indicated, all sales growth figures in this press release are stated on a comparable basis (see appendix 7 for a definition)

(1) See appendix 7 for a definition of financial indicators

(2) Adjusted EPS excluding selected items

Transforming sanofi-aventis into a diversified global leader in healthcare

Sanofi-aventis has core strengths in the field of healthcare: a global presence, market leadership in vaccines, major biological products (such as Lovenox(R) and Lantus(R)) and a strong and long-established presence in emerging markets, not to mention a track record of adapting cost structures and a solid financial situation. But although these are solid foundations, we need to develop new growth platforms in light of the important challenges of patent expirations and declining R&D productivity facing the pharmaceutical industry. Our response to these challenges is an ambitious one: to deliver sustainable growth, we need to transform ourselves into a diversified global healthcare leader.

This is why we have initiated a wide-ranging transformation program, focusing on three key themes:

  • Increasing innovation in Research & Development

We have begun a complete and objective review of our research portfolio, in order to reassess the allocation of resources. This review has already led to a rationalization of our portfolio and will be ongoing in the first half of 2009. In the future, we must focus our R&D strategy on key technologies and diseases to better
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
3. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
4. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
5. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
6. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
7. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
8. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
9. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
10. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
11. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin ... ProPin to pin point locations on a map, to indicate prices ... allows users to choose from 30 simplistic presets with geometric design ... video editors can easily manipulate ProPin presets as a whole. ... ease. , Using ProPin is easy, simply drag a preset into ...
(Date:5/24/2015)... May 24, 2015 A report ... that the single best option for avoiding cardiovascular disease ... fitness level was the single most powerful predictor of ... such as diabetes and family history of premature death ... lifelong heart and lung fitness. , The Importance of ...
(Date:5/23/2015)... 23, 2015 With the implementation of ... finding it increasingly difficult to provide their employees with ... provide adequate insurance for employees stand to face strict ... an integral part of a business’s success or failure. ... businesses, Online USA Doctors has created a varying level ...
(Date:5/23/2015)... A live auction will be held to sell ... and other medical facilities around the United States. Various ... surgery, anesthesia, exam and much more. , The live ... 28 starting at 9:00am CDT each day. The equipment is ... Melrose Park, IL 60160. Anyone can participate in the ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 ... technology, communication and capacity are intersecting to create ... across society, the opening speaker at WesternU's 34th ... California Lieut. Gov. Gavin Newsom, a former San ... the keynote speaker at the graduation ceremony for ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3
... a recently-formed, New Jersey-based biotechnology company, applies ... scale protein production, Nuclear Magnetic Resonance (NMR), ... discovery efforts. Nexomics Biosciences has signed ... State University of New Jersey, that provides ...
... Jan. 20 Nationwide Health Properties, Inc. (NYSE: NHP ) announced the tax treatment for ... year 2008:, COMMON STOCK (CUSIP# 638620104), 2008 ... Taxable Return Total Unrecaptured, ... Capital Section, Date ...
... Usage of Controversial App , ... (PRWEB) January 20, ... there is some very unfortunate confusion as to the intentions of ... entitled "Teen Torture". Due to its attention-grabbing name, and the ...
... Inc. (Nasdaq: OMCL ), a leading provider ... its 2008 year end guidance and provided initial guidance ... a reorganization focused on driving sales through higher levels ... results to be consistent with previous guidance of 18% ...
... offer doctors a better assessment of patient,s condition, chances of ... images of post-heart attack bleeding within the heart have been ... College London team said their research shows that the amount ... a heart attack. The use of this kind of imaging, ...
... While the U.S. Food and Drug Administration (FDA) and ... week,s Peanut Corporation of America (PCA) recall it is important ... of jarred peanut butter are not affected by the PCA ... , , In addition, although some food ...
Cached Medicine News:Health News:New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground 2Health News:New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground 3Health News:NHP Announces Tax Treatment of 2008 Distributions 2Health News:NHP Announces Tax Treatment of 2008 Distributions 3Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 2Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 3Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 2Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 3Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 4Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 5Health News:MRI Scans Reveal Post-Heart Attack Bleeding 2
(Date:5/22/2015)... , May 22, 2015 /CNW/ - More than fifty ... to treat morning sickness in expectant mothers. Tragically, Thalidomide caused ... and families. Support has been provided to ... Government of Canada in 1991 and ... absence of a legal obligation to provide support, we have ...
(Date:5/22/2015)... , May 22, 2015 The ... the $13 billion global cardiac rhythm management device ... Kalorama found that Medtronic, St. Jude Medical, Boston ... 80% of this market segment. The healthcare market ... Markets , uses 2015 as a base year, ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... Administration (FDA) approved the use of once-daily INTUNIV® (guanfacine) ... treatment of attention deficit hyperactivity disorder (ADHD) in children and ... treatment program. The approval is based on results from a ...
... specialist in genome customization and subsidiary of Cellectis (Alternext: ... custom TALEN(1). Recognized as a pioneer in ... Cellectis bioresearch brings today the life sciences community a ... of cell. The service will start with ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Cellectis bioresearch Makes Genome Engineering Affordable for All Users 2
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Valproic Acid in human serum...
For the quantitative in vitro determination of Microalbumin in human urine....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Medicine Products: